Best MRD outcome in 14 responding patients treated off-trial with venetoclax plus azacitidine using the ddPCR technique. Between 1 and 3 mutations identified on diagnostic NGS were monitored throughout therapy for patients who achieved a morphologic remission with venetoclax plus azacitidine, had baseline mutations or mutations that could be followed with ddPCR, and had available follow-up bone marrow samples (N = 14). The maximal decrease in VAF (normalized percentage of decrease in VAF from baseline) is shown on the y-axis; individual mutations for each patient are shown on the x-axis. Four patients (green bars) had MRD negativity and remain in remission. Five patients (red bars) were MRD⁺ and relapsed. Six patients (blue bars) were MRD⁺ but have not relapsed at the time of data censoring. *Individual mutations that were undetectable at best response (<0.01% VAF).